Effects of Astragaloside IV on Heart Failure in Rats

Overview

Journal Chin Med

Publisher Biomed Central

Specialty Biomedical Engineering

Date 2009 Apr 3

PMID 19338675

Citations 20

Authors

Zhuanyou Zhao

Weiting Wang

Fang Wang

Kerui Zhao

Yingmei Han

Weiren Xu

Lida Tang

Affiliations

Soon will be listed here.

Abstract

Background: Astragaloside IV (ASI) in Radix Astragali is believed to be the active component in treating heart failure. The present study aims to examine the effects of ASI on cardiovascular parameters in long-term heart failure in rats.

Methods: Using echocardiographic and haemodynamic measurements, we studied the effects of ASI on congestive heart failure (CHF) induced by ligation of the left coronary artery in rats.

Results: ASI (0.1, 0.3 and 1.0 mg/kg/day) attenuated the decline of fractional shortening (FS). The peak derivatives of the left ventricle (LV) pressure (dp/dt) in ASI-treated groups significantly increased. Both LV internal diameters in diastole (LVIDd) and in systole (LVIDs) decreased significantly after ASI treatment (0.3 and 1.0 mg/kg/day). ASI (1.0 mg/kg/day) attenuated the decrease of LV systolic pressure (LVSP). ASI treatment inhibited compensatory hypertrophy of myocardial cells and lowered the number of apoptotic myocytes.

Conclusion: ASI improved cardiac functions as measured by cardiovascular parameters.

Citing Articles

The recent advance and prospect of natural source compounds for the treatment of heart failure.

Chen X, Liu S, Li S, Feng J, Hu Y, Cheng X Heliyon. 2024; 10(5):e27110.

PMID: 38444481 PMC: 10912389. DOI: 10.1016/j.heliyon.2024.e27110.

Effect of Astragaloside IV on improving cardiac function in rats with heart failure: a preclinical systematic review and meta-analysis.

Zhang Z, Zhang M, Xu Y, Lu M, Zhang L, Li C Front Pharmacol. 2023; 14:1226008.

PMID: 37854719 PMC: 10579795. DOI: 10.3389/fphar.2023.1226008.

Quantification of Cardiomyocyte Contraction In Vitro and Drug Screening by MyocytoBeats.

Cheng Z, Yang Y, Jiang K, Nie H, Yang X, Tu Z J Cardiovasc Transl Res. 2023; 16(4):758-767.

PMID: 36715820 DOI: 10.1007/s12265-023-10357-x.

The Chemistry and the Anti-Inflammatory Activity of Polymethoxyflavonoids from Genus.

Fontana G, Bruno M, Sottile F, Badalamenti N Antioxidants (Basel). 2023; 12(1).

PMID: 36670885 PMC: 9855034. DOI: 10.3390/antiox12010023.

Astragaloside IV attenuate MI-induced myocardial fibrosis and cardiac remodeling by inhibiting ROS/caspase-1/GSDMD signaling pathway.

Zhang X, Qu H, Yang T, Liu Q, Zhou H Cell Cycle. 2022; 21(21):2309-2322.

PMID: 35770948 PMC: 9586672. DOI: 10.1080/15384101.2022.2093598.

References

Ahmet I, Krawczyk M, Heller P, Moon C, Lakatta E, Talan M . Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation. 2004; 110(9):1083-90. DOI: 10.1161/01.CIR.0000139844.15045.F9. View

Schiller N, Shah P, Crawford M, DeMaria A, Devereux R, FEIGENBAUM H . Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989; 2(5):358-67. DOI: 10.1016/s0894-7317(89)80014-8. View

Li Z, BING O, Long X, Robinson K, Lakatta E . Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. Am J Physiol. 1997; 272(5 Pt 2):H2313-9. DOI: 10.1152/ajpheart.1997.272.5.H2313. View

Prunier F, Gaertner R, Louedec L, Michel J, Mercadier J, Escoubet B . Doppler echocardiographic estimation of left ventricular end-diastolic pressure after MI in rats. Am J Physiol Heart Circ Physiol. 2002; 283(1):H346-52. DOI: 10.1152/ajpheart.01050.2001. View

BING O . Hypothesis: apoptosis may be a mechanism for the transition to heart failure with chronic pressure overload. J Mol Cell Cardiol. 1994; 26(8):943-8. DOI: 10.1006/jmcc.1994.1115. View

Dalla Libera L, Ravara B, Angelini A, Rossini K, Sandri M, Thiene G . Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure. Circulation. 2001; 103(17):2195-200. DOI: 10.1161/01.cir.103.17.2195. View

Yoshiyama M, Takeuchi K, Omura T, Izutani S, Nakamura Y, Akioka K . Effect of diltiazem on cardiac remodeling in rats assessed by Doppler echocardiography and mRNA expression. Cardiovasc Drugs Ther. 1999; 13(3):249-58. DOI: 10.1023/a:1007752310881. View

Oie E, Bjornerheim R, Clausen O, Attramadal H . Cyclosporin A inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats. Am J Physiol Heart Circ Physiol. 2000; 278(6):H2115-23. DOI: 10.1152/ajpheart.2000.278.6.H2115. View

Omerovic E, Bollano E, Basetti M, Kujacic V, Waagstein L, Hjalmarson A . Bioenergetic, functional and morphological consequences of postinfarct cardiac remodeling in the rat. J Mol Cell Cardiol. 1999; 31(9):1685-95. DOI: 10.1006/jmcc.1999.1004. View

10.

Khoynezhad A, Jalali Z, Tortolani A . A synopsis of research in cardiac apoptosis and its application to congestive heart failure. Tex Heart Inst J. 2007; 34(3):352-9. PMC: 1995053. View

11.

Tonnessen T, Christensen G, Oie E, Holt E, Kjekshus H, Smiseth O . Increased cardiac expression of endothelin-1 mRNA in ischemic heart failure in rats. Cardiovasc Res. 1997; 33(3):601-10. DOI: 10.1016/s0008-6363(96)00266-0. View

12.

Vescovo G, Volterrani M, Zennaro R, Sandri M, Ceconi C, Lorusso R . Apoptosis in the skeletal muscle of patients with heart failure: investigation of clinical and biochemical changes. Heart. 2000; 84(4):431-7. PMC: 1729437. DOI: 10.1136/heart.84.4.431. View

13.

Burrell L, Chan R, Phillips P, Calafiore P, Tonkin A, Johnston C . Validation of an echocardiographic assessment of cardiac function following moderate size myocardial infarction in the rat. Clin Exp Pharmacol Physiol. 1996; 23(6-7):570-2. DOI: 10.1111/j.1440-1681.1996.tb02782.x. View

14.

Francis G . Pathophysiology of chronic heart failure. Am J Med. 2001; 110 Suppl 7A:37S-46S. DOI: 10.1016/s0002-9343(98)00385-4. View

15.

Luo H, Dai R, Li Y . [Nuclear cardiology study on effective ingredients of Astragalus membranaceus in treating heart failure]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1995; 15(12):707-9. View

16.

Zhang Z, Li S, Yang Y, Chen R, Ge J, Chen H . Effect of astragaloside on cardiomyocyte apoptosis in murine coxsackievirus B3 myocarditis. J Asian Nat Prod Res. 2007; 9(2):145-51. DOI: 10.1080/10286020412331286506. View

17.

Narula J, Haider N, Virmani R, DiSalvo T, Kolodgie F, Hajjar R . Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 1996; 335(16):1182-9. DOI: 10.1056/NEJM199610173351603. View

18.

Kobara M, Tatsumi T, Kambayashi D, Mano A, Yamanaka S, Shiraishi J . Effects of ACE inhibition on myocardial apoptosis in an ischemia-reperfusion rat heart model. J Cardiovasc Pharmacol. 2003; 41(6):880-9. DOI: 10.1097/00005344-200306000-00008. View

19.

Sjaastad I, Sejersted O, Ilebekk A, Bjornerheim R . Echocardiographic criteria for detection of postinfarction congestive heart failure in rats. J Appl Physiol (1985). 2000; 89(4):1445-54. DOI: 10.1152/jappl.2000.89.4.1445. View

20.

Hagar J, Matthews R, Kloner R . Quantitative two-dimensional echocardiographic assessment of regional wall motion during transient ischemia and reperfusion in the rat. J Am Soc Echocardiogr. 1995; 8(2):162-74. DOI: 10.1016/s0894-7317(05)80405-5. View